Bavachalcone targets transferrin receptor and sensitizes gemcitabine to affect bladder cancer progression

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Gemcitabine resistance is a major challenge in bladder cancer treatment, leading to disease recurrence and progression.
• Identifying novel therapeutic strategies to overcome chemoresistance is crucial for improving patient outcomes.

Purpose of the Study:

• To identify novel compounds that sensitize bladder cancer cells to gemcitabine.
• To elucidate the mechanism of action of identified compounds.
• To evaluate the therapeutic potential of combining the novel compound with gemcitabine in preclinical models.

Main Methods:

• High-throughput drug screening of bladder cancer cell lines.
• Mechanistic studies involving transferrin receptor (TFRC) and epidermal growth factor receptor (EGFR) inhibition.
• Assessment of cellular iron utilization, mitochondrial respiration, and DNA damage repair.
• Combination therapy studies in patient-derived xenograft models.

Main Results:

• Bavachalcone (Bava) was identified as a potent gemcitabine sensitizer.
• Bava inhibits TFRC and EGFR, reducing iron influx and disrupting mitochondrial function.
• The Bava-gemcitabine combination synergistically enhanced anti-tumor efficacy by inhibiting DNA repair and the ATR-CHEK1-E2F1 pathway, while downregulating RRM1.
• Elevated TFRC and RRM1 expression correlated with poor prognosis in bladder cancer patients.

Conclusions:

• Bavachalcone is the first small-molecule TFRC inhibitor that overcomes gemcitabine resistance via iron modulation.
• The Bava-gemcitabine combination represents a promising therapeutic strategy for bladder cancer.
• TFRC and RRM1 serve as potential biomarkers for bladder cancer prognosis.